Lupin Gains FDA Tentative Nod for Higher-Dose Enzalutamide Generics — Lupin Pharmaceuticals, Inc.

Event summary

Lupin received tentative FDA approval for its generic Enzalutamide tablets in 40mg, 80mg, 120mg, and 160mg strengths on June 26, 2026.
The approval covers bioequivalent versions of Astellas' Xtandi® Tablets for the same indications.
Lupin's higher-dose formulations (120mg and 160mg) offer alternative dosing options not currently available in the branded product.
This marks Lupin's entry into the prostate cancer treatment market with a complex generic.

The big picture

This approval positions Lupin as a competitor in the oncology space, particularly for prostate cancer treatments. The inclusion of higher-dose strengths could differentiate their offering and potentially expand treatment options. The move comes amid increasing pressure on branded drug revenues from generic alternatives, reflecting broader industry trends toward cost-effective therapies.

What we're watching

Market Penetration: How quickly Lupin can capture market share from Astellas' Xtandi in the prostate cancer space.
Regulatory Pathway: Whether this tentative approval converts to full approval and the timeline for commercial launch.
Pricing Strategy: How Lupin prices its higher-dose formulations against the existing branded options.